CN101904861A - Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity - Google Patents
Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity Download PDFInfo
- Publication number
- CN101904861A CN101904861A CN 201010216628 CN201010216628A CN101904861A CN 101904861 A CN101904861 A CN 101904861A CN 201010216628 CN201010216628 CN 201010216628 CN 201010216628 A CN201010216628 A CN 201010216628A CN 101904861 A CN101904861 A CN 101904861A
- Authority
- CN
- China
- Prior art keywords
- saccharomyces cerevisiae
- rna
- immunity
- metabolism
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an application Saccharomyces cerevisiae RNA in preparing a medicine for promoting biologic metabolism and immunity. Saccharomyces cerevisiae RNA 25s and 18s sequences and human RNA 28s and 18s sequences are highly homological, so the sequences have high homogeny, high compatibility and high safety and can be easily absorbed and utilized by human body. The Saccharomyces cerevisiae RNA can facilitate the synthesis of the ribosomal DND nucleate of human body so as to activate the biologic metabolism and promote immunity.
Description
Technical field:
The present invention relates to the purposes of a kind of saccharomyces cerevisiae ribosome (RNA), the application of especially a kind of saccharomyces cerevisiae RNA in preparation raising organism metabolism and immunity medicine.
Background technology:
Saccharomyces cerevisiae (Saccharomyces cerevisiae) claim bakery yeast or budding yeast again, is the fungal bacterial strain that can be used for health food that ministry of Health of China first is recommended.The cell of saccharomyces cerevisiae is spherical or avette, and diameter 5-10 μ m contains protein about 50%, and the amino acid content height is rich in vitamin B group, also has abundant enzyme system and diversified economy to be worth very high biological active substances.Prehuman in several thousand in the modern food industrial aspect, is widely used as the good leaven and the nutrient of food such as human bread as basic food, steamed bread, steamed bun, cookies cake just with bakery yeast fermentation bread and drinks.
Summary of the invention:
The present invention finds all height homologies of saccharomyces cerevisiae ribosome (RNA) 25s, 18s sequence and human corresponding ribosome (RNA) 28s, 18s sequence, has invented the application of saccharomyces cerevisiae RNA in preparation raising organism metabolism and immunity medicine.
Technical solution of the present invention is: the application of a kind of saccharomyces cerevisiae RNA in preparation raising organism metabolism and immunity medicine.
The present invention prepares medicine with saccharomyces cerevisiae RNA, because saccharomyces cerevisiae ribosome (RNA) 25s, 18s sequence and human corresponding ribosome (RNA) 28s, 18s sequence be the height homology all, thereby have high homogeneity and a high-compatibility, thereby has high security, easilier be absorbed by the body and utilize, can promote human body internal ribosome nucleic acid synthetic better, thus activation organism metabolism and raising body immunity.
The specific embodiment:
Experimental example 1:
One. get a large amount of saccharomyces cerevisiae preservation strains, obtain the higher original strain Y37 of a strain nucleic acid content through primary dcreening operation and multiple sieve, on 100 cubic metres of hoisting type fermentation tanks, carry out continuous fermentation, the thalline that in incubation, obtains, extract ribonucleic acid, i.e. saccharomyces cerevisiae RNA through high temperature Sal method.
Utilize nucleic acid database foremost in the world, that know best---the GenBank (gene library) of U.S. biotechnology information centre, consulted and analyzed a large amount of gene mappings, respectively saccharomyces cerevisiae RNA 25s, 18s sequence and human corresponding ribosomal RNA 28s, 18s sequence are carried out homology comparison (seeing Table 1), both are the height homology all.
Table 1
Annotate: 1) bp: base pair
2) percent is the percentage of homologous nucleotide sequence
Improve organism metabolism and immunity medicine with saccharomyces cerevisiae RNA preparation.
Two. the safety evaluatio result of the embodiment of the invention:
1. acute oral toxicity test:, belong to non-poisonous material to female, male KM chmice acute per os MTD＞21.50g/kgbw; To female, the great and mighty or powerful Mus acute oral of SD MTD＞21.5g/kgbw, belong to non-poisonous material.
2. genetic toxicity test: the result is all negative for three genetic toxicity tests (Salmonella reversion test, mouse bone marrow cells are had a liking for many micronucleus in erythrocytes tests and mouse sperm deformity test).
3.30 it feeding trial: with 1.25,2.50,5.00g/kgbw dosage, sneak into feedstuff in 1.25%, 2.50% and 5.00% ratio, mixing feeds brought Mus up 30 days; The control rats feed does not add the normal feedstuff 30 days of the embodiment of the invention.The result shows, experimental session, and each treated animal growth promoter is good, and each dosage of the embodiment of the invention does not have tangible harmful effect to rat body weight, weightening finish, per day food-intake and food utilization.The experiment end, 5.00g/kgbw organize female, male Mus blood sugar increasing (P＜0.05), dirty weight of female Hepar Mus and liver/body ratio increases (P＜0.01), kidney weight and kidney/body ratio and increases (P＜0.01 and 0.05), and male Mus testis/body ratio increases (P＜0.01): 2.50g/kgbw and organizes female Ren Mus/body ratio and male Mus testis/body ratio rising (P＜0.05).1.25g/kgbw the group blood biochemical learn every index with every dirty/body ratio compares with tester, there is no notable difference or the change of clinical meaning arranged.Each dosage group hematological indices and matched group compare, there was no significant difference (P＞0.05).Gross anatomy is not seen the abnormal change relevant with being subjected to the sample product with tissue pathology checking.
Three. the embodiment of the invention is to the influence of mouse antibodies cellulation
Antibody-producting cell detects (Jerne improves slide method):
Through variance analysis, F=9.6204, P=0.0001.300mg/kg.bw the dosage group is compared with control group mice, its antibody-producting cell is counted there was no significant difference (P＞0.05); 600mg/kg.bw compare with control group mice with 900mg/kg.bw dosage group, there were significant differences for its antibody-producting cell number average (P＜0.01), sees Table 2.
Table 2. saccharomyces cerevisiae RNA is to the influence of mouse antibodies cellulation
*Expression is compared with matched group, P＜0.01
Four. the embodiment of the invention is engulfed the influence of chicken red blood cell ability to Turnover of Mouse Peritoneal Macrophages
Phagocytic percentage: through variance analysis, F=4.0819, P=0.0130.300mg/kg.bw compares with control group mice with 600mg/kg.bw dosage group, and its peritoneal macrophage is engulfed the phagocytic percentage of chicken red blood cell there are no significant difference (P＞0.05); 900mg/kg.bw the dosage group is compared with control group mice, the phagocytic percentage that its peritoneal macrophage is engulfed chicken red blood cell has significant difference (P＜0.05), sees Table 3.
Phagocytic index: through variance analysis, F=8.1078, P=0.0003.300mg/kg.bw the dosage group is compared with control group mice, its peritoneal macrophage is engulfed the phagocytic index there was no significant difference (P＞0.05) of chicken red blood cell; 600mg/kg.bw the dosage group is compared with control group mice, the phagocytic percentage that its peritoneal macrophage is engulfed chicken red blood cell all has significant difference (P＜0.05); 900mg/kg.bw the dosage group is compared with control group mice, the phagocytic percentage that its peritoneal macrophage is engulfed chicken red blood cell has significant difference (P＜0.01), sees Table 3.
Table 3. saccharomyces cerevisiae RNA engulfs the influence of chicken red blood cell ability to Turnover of Mouse Peritoneal Macrophages
Per os gives mice (Balb/c) 300mg/kgbw, 600mg/kgbw and 900mg/kgbw dosage saccharomyces cerevisiae RNA, tests after 30 days.In mice serum hemolysin determination test, each dosage group is compared with control group mice, and its antibody product all has significant difference.600mg/kgbw compares with control group mice with 900mg/kgbw dosage group in the antibody-producting cell test experience, and its antibody-producting cell number average has significant difference.Engulf in the chicken red blood cell test in Turnover of Mouse Peritoneal Macrophages, 900mg/kgbw dosage group is compared with control group mice, and the phagocytic percentage that its peritoneal macrophage is engulfed chicken red blood cell has significant difference.600mg/kgbw compares with control group mice with 900mg/kgbw dosage group, and the phagocytic percentage that its peritoneal macrophage is engulfed chicken red blood cell has significant difference.Clean up in the experiment at mice carbon, each dosage group is compared with control group mice, and its phagocytic index a all has significant difference.Can think that according to evaluation criterion saccharomyces cerevisiae RNA has the enhancing immunity function.
Claims (1)
1. the application of saccharomyces cerevisiae RNA in preparation raising organism metabolism and immunity medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010216628 CN101904861A (en) | 2010-07-05 | 2010-07-05 | Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010216628 CN101904861A (en) | 2010-07-05 | 2010-07-05 | Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101904861A true CN101904861A (en) | 2010-12-08 |
Family
ID=43260549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010216628 Pending CN101904861A (en) | 2010-07-05 | 2010-07-05 | Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101904861A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108660085A (en) * | 2018-05-30 | 2018-10-16 | 天津科技大学 | One plant height produces nucleic acid saccharomyces cerevisiae engineered yeast and its construction method and application |
| CN108841737A (en) * | 2018-05-30 | 2018-11-20 | 天津科技大学 | One plant of high yield nucleic acid saccharomyces cerevisiae engineered yeast containing Rpf1p gene and its construction method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101262883A (en) * | 2005-07-11 | 2008-09-10 | 环球免疫公司 | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| CN101480220A (en) * | 2008-11-07 | 2009-07-15 | 江苏省苏微微生物研究有限公司 | Method for preparing mixed type nucleotide feed addictive from yeast cell and application |
-
2010
- 2010-07-05 CN CN 201010216628 patent/CN101904861A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101262883A (en) * | 2005-07-11 | 2008-09-10 | 环球免疫公司 | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| CN101480220A (en) * | 2008-11-07 | 2009-07-15 | 江苏省苏微微生物研究有限公司 | Method for preparing mixed type nucleotide feed addictive from yeast cell and application |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108660085A (en) * | 2018-05-30 | 2018-10-16 | 天津科技大学 | One plant height produces nucleic acid saccharomyces cerevisiae engineered yeast and its construction method and application |
| CN108841737A (en) * | 2018-05-30 | 2018-11-20 | 天津科技大学 | One plant of high yield nucleic acid saccharomyces cerevisiae engineered yeast containing Rpf1p gene and its construction method and application |
| CN108841737B (en) * | 2018-05-30 | 2020-09-29 | 天津科技大学 | Nucleic acid-producing saccharomyces cerevisiae engineering bacterium containing Rpf1 gene and construction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Techaparin et al. | High-temperature ethanol production using thermotolerant yeast newly isolated from Greater Mekong Subregion | |
| Ciani et al. | Microbes: food for the future | |
| Sui et al. | Dunaliella microalgae for nutritional protein: an undervalued asset | |
| Jacob et al. | Spent yeast from brewing processes: a biodiverse starting material for yeast extract production | |
| CN104703611B (en) | For producing the multi-stage method of immunomodulator | |
| Ukaegbu-Obi | Single cell protein: a resort to global protein challenge and waste management | |
| Konur | Glycerol: A scientometric review of the research | |
| Zielinski et al. | Biological activity of hydrophilic extract of Chlorella vulgaris grown on post-fermentation leachate from a biogas plant supplied with stillage and maize silage | |
| Amorim et al. | Influence of acerola pulp concentration on mead production by Saccharomyces cerevisiae AWRI 796 | |
| Azaizeh et al. | Production of lactic acid from carob, banana and sugarcane lignocellulose biomass | |
| CN103923869A (en) | Bacillus subtilis gene engineering bacterial producing Neu5Ac, construction method and application thereof | |
| WO2023098678A1 (en) | High-protein saccharomyces cerevisiae and application thereof | |
| CN101928674A (en) | Method for breeding high-nucleic acid yeast and method for preparing ribonucleic acid by using high-nucleic acid yeast | |
| Castillo-Castillo et al. | Isolation and characterization of yeasts from fermented apple bagasse as additives for ruminant feeding | |
| Thiviya et al. | Production of single-cell protein from fruit peel wastes using palmyrah toddy yeast | |
| Galli et al. | Antioxidant properties of sourdoughs made with whole grain flours of hull-less barley or conventional and pigmented wheat and by selected lactobacilli strains | |
| CN101904861A (en) | Application of Saccharomyces cerevisiae RNA in preparing medicine for promoting biologic metabolism and immunity | |
| Canelli et al. | Amino acid profile and protein bioaccessibility of two Galdieria sulphuraria strains cultivated autotrophically and mixotrophically in pilot-scale photobioreactors | |
| CN102174414B (en) | Application of new morchella costata M8-13 liquid fermentation substance in development of health-care products and medicaments | |
| CN104780943B (en) | New agar oligosaccharides complex composition prepared by DagA enzyme reactions, with anti-fat and anti-diabetic effect, agar source | |
| Kayacan et al. | Adaptive evolution of industrial Brewer’s yeast strains towards a snowflake phenotype | |
| Sukhikh et al. | Evaluation of the prospects for the use of microalgae in functional bread production | |
| Li et al. | Comparative transcriptomic analyses reveal the regulatory mechanism of nutrient limitation-induced sporulation of Antrodia cinnamomea in submerged fermentation | |
| Lachance et al. | Yeasts | |
| CN104171426A (en) | Micro-ecological composite additive for black-bone chicken and preparation method of micro-ecological composite additive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20101208 |